Dianthus Therapeutics (DNTH) CEO On Biotech & Merger

Dianthus Therapeutics (DNTH) is a clinical-stage biotech company that develops antibody complement therapeutics. CEO Marino Garcia joins Oliver Renick to discuss DNTH. DNTH completed a merger with Magenta Therapeutics and began trading on the NASDAQ under the ticker “DNTH.” DNTH announced positive top-line phase 1 data for DNTH103 treatment. Tune in to find out more about the stock market today.

Morning Trade Live

15 Sep 2023

SHARE

Schwab Network's Newsletters

Daily insights for every investor

ON AIR
10:00 am
Trading 360
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Schwab 2026 Outlook
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
ON AIR
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Liz Ann Live
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Liz Ann Live
REPLAY
10:30 pm
The Wrap
REPLAY